Celgene pays Dragonfly $50M to expand NK cell immunotherapy deal

Celgene Corp. (NASDAQ:CELG) expanded its deal with Dragonfly Therapeutics Inc. (Waltham, Mass.), doubling the number of trispecific NK cell engager cancer compounds

Read the full 227 word article

User Sign In